Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Catumaxomab Intra- and Postoperative in Ovarian Cancer
NCT00563836Phase 2Completed
- Sponsor
- Neovii Pharmaceuticals
- Start
- Nov 2007
- Primary completion
- Sep 2008
- Modality
- Bispecific Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of catumaxomab in epithelial ovarian cancer (EOC), sponsored by Neovii Pharmaceuticals. Primary endpoint: Rate of all specific postoperative complications newly observed during a period of 30 days after surgery. Started Nov 2007; status: completed.
02
Drugs
catumaxomab
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT00563836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00563836.